From: Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study
The best response (N = 42)
No. (%)
CR
0 (0%)
PR
22 (52.5%)
SD
14 (33.3%)
PD
6 (14.3%)
ORR (CR + PR)
DCR (CR + PR + SD)
36 (85.7%)